What the Research Says
Lutein has robust clinical evidence, anchored by the AREDS2 trial (2013, JAMA, n=4,203), which established lutein 10 mg + zeaxanthin 2 mg as the preferred carotenoid combination for AMD. A 10-year follow-up confirmed lutein/zeaxanthin was superior to beta-carotene for reducing late AMD risk by approximately 20%. Epidemiological data consistently associates higher lutein intake with reduced risk of both AMD and cataracts.
